Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Shares of Recursion Pharmaceuticals are up 16.02% at $4.78. The company is worth $2.56B, number 2603 out of 3132 on our list.
The 52-week range is $2.77 to $7.18. Today's price is about 46% of the way from the low to the high. Holders are behind 13.6% over twelve months, but up 24.5% across the last three months.
On the chart it holds above both the 50-day ($3.45) and 200-day ($3.58) moving averages; RSI is 72, which some call overbought, and the last 30 sessions moved at roughly 90% annualized volatility.
5 analysts follow the stock and the average call is "buy". The mean target, $6.65, sits 39.1% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 3132 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
5 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
RXRX is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $6.65, 39.1% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $5.73, so shares trade 16.6% below that estimate. On earnings multiple, it sits in the 49th percentile of its own five-year valuation range (cheaper than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +28.5% | Bullish |
| Price vs 50-day average | +38.4% | Bullish |
| Price vs 200-day average | +33.7% | Bullish |
| 50-day vs 200-day | 50d below 200d | Bearish |
| RSI (14) | 71.8 | Neutral |
| MACD (12,26,9) | 0.25 | Bullish |
| Bollinger band position | 112% | Neutral |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 6, 2026 3:20 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,132 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$4.78 is the latest print for RXRX, a move of +16.02% against yesterday's close of $4.12. Today's low and high so far: $4.06 and $4.94.
Equity value comes to $2.56B at the current price. By that measure it is number 2603 of the 3132 names in our coverage.
The year's floor is $2.77 and the ceiling $7.18. Shares are 33.4% away from that ceiling.
Our data shows no dividend paid by Recursion Pharmaceuticals over the trailing twelve months.
Of 5 analysts, 40% say buy, 60% hold and 0% sell. Price targets average $6.65, with the most cautious at $5.30 and the most optimistic at $8.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on RXRX.